Wall Street Researcher

QHSLab Inc

USAQ  OTCQB

BREAKOUT TERRITORY

MEDICAL DEVICE – DIGITAL HEALTHCARE SOLUTIONS

REMOTE PATIENT MONITORING – NEW ALERGY QUICK TEST

This medical device and digital healthcare company is in the spotlight as new medical products and medical services are being developed and enhanced . These shares have tested its 50 day resistance level of $0.53 cents and we feel could break above that level shortly. With a yearly high recorded earlier this year at $1.00 and we look for a secondary move towards that level shortly

We expect this company to provide investors with significant gains in the coming months and we feel that all serious investors should watch these shares carefully . Any move above the $0.53 cent level would be considered a BREAKOUT to the upside . With a small float we would expect upside volatility once the investment community takes notice.

__________________________________________

QHSLab Inc is a medical device technology and software as a service (SaaS) company focused on enabling primary care physicians (PCP’s) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.

In some cases, the products we provide our physician clients will enable them to diagnose and treat patients with chronic diseases which they historically have referred to specialists, allowing them to increase their practice revenue.

As part of the company’s mission, they  provide PCP’s with the software, training and devices necessary to allow them to treat their patients using value-based healthcare, informatics and algorithmic personalized medicine, including digital therapeutics. Our digital healthcare and point of care solutions also support remote patient monitoring, to address chronic care and preventive medicine and are reimbursable to the medical practice.

WEBSITE    TEAM    ABOUT   VIDEO   FORM 10 K    UPDATE

New $90 million annual addressable market for QHSLab’s latest product, the Allergy Quick Test, branded AllergiQT(TM).

WEST PALM BEACH, FL, May 10, 2022 (GLOBE NEWSWIRE) — QHSLab, Inc. (OTCQB: USAQ) a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging point of care technologies, projects a new $90 million annual addressable market for the Company’s latest product, the Allergy Quick Test, branded AllergiQT  .

Recently obtained data indicates an attractive market opportunity awaits the Company’s latest allergy skin test device, the AllergiQT  – Quick Test, a simple in office allergy test designed specifically for primary care. The test is administered on the forearms so there is no need for the patient to undress, no drawing of blood, and the results are available in 15 minutes or less.

As of early May 2022, there were some 30,699 family medicine, pediatrician and non-allergy specialist physicians regularly ordering allergy blood tests. Based on our considerable experience with our AllergiEnd ® Test, we believe a broad segment of the PCP market would be interested in a simplified allergy test system like the Allergy Quick Test. Laboratory blood tests are costly, ranging from $220 to over $500 and they don’t offer the physician any reimbursement for performing the test. The AllergiQT  – Quick Test will cost an insurance company less than $100 per test and the doctor’s office bills and receives the reimbursement for performing the test without the need for a laboratory. The resulting reimbursement is much needed income for primary care practices.

The AllergiQT  – Quick Test replaces the need for blood testing with a simple skin scratch test performed in the physician’s office during a routine office visit. Patients and doctors no longer have to wait for lab test results, no needles are needed to extract blood, and skin testing provides more sensitive findings for physicians to begin evidence-based treatment. The virtually pain free procedure measures in a matter of minutes the actual reaction to the allergen, not just antibodies in the blood, this shows the physician exactly how the immune system is reacting when the patient comes into contact with the environmental or food allergens that are being tested.

AllergiQT  – Quick Test provides allergen screening for the most common allergens, including cat, dog, dust, cockroach, mold, shellfish, nuts, milk, egg, grasses, weeds and trees.

There are over 250,000 independent primary care physicians in the US targeted for this product and more than 60 million allergy suffering patients each year suggesting the addressable market for QHSLab’s allergy product line is even much larger than current data suggests.

“This is true value-based care, lowering healthcare costs and providing information needed to help improve patient outcomes.” states Troy Grogan, President and CEO at QHSLab, Inc.

Key aspects of the AllergiQT   Quick Test include:

  • Targeting non-allergy specialists in primary care settings .
  • $90 million addressable current annual market .
  • The Allergi QT  test is minimally-invasive and can be easily administered during an office visit.
  • Two multiple head test applicators are placed on the forearms of a patient during a routine physical examination Results in 15 minutes.
  • NO MORE NEEDLES!
  • The twenty-allergen allergy skin test kit includes a broad spectrum of environmental and food allergens.
  • Within 15 minutes , if the patient has any allergic reactions, the physician can easily identify the allergen and offer a prescription remedy to begin treatment during the same office visit , there is no waiting for lab test results.
  • Lower costs for insurance companies and new reimbursements for primary care physicians.
  • Allergi QT  quick test results offer physicians the ability to employ evidence-based medicine s that treat the cause of allergies , not merely the symptoms, by providing prescription medicines formulated to overcome the source of the allergic reaction.

QHSLab. Issues Update and Investor Presentation May 2022

  • Superior Business Model and Strategic Position Validated By Repeat Ordering Client Base and New Developments to Product Portfolio
  • Addressable Market Opportunity Includes Over 250,000 Independent Primary Care Physicians
  • Favorably Aligned with Industry Drivers Including Increasing Acceptance of Digital Health, Point of Care and Virtual Care Services by Third Party Payers
  • Focused on Continuing Strategic Acquisition Plan To Leverage Across Expanding Distribution Network and Customer Footprint

WEST PALM BEACH, FL, May 09, 2022 (GLOBE NEWSWIRE) — QHSLab, Inc. (OTCQB: USAQ) a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point of care technologies, announces an update to the Company’s corporate presentation highlighting the Company’s 2021 achievements and future plans underway.

QHSLab, Inc. is a medical device technology company focused on enabling primary care physicians (PCPs) to increase their revenues by providing value-based tools to evaluate and treat chronic disease through reimbursable procedures.

“We founded QHSLab off the backs of two cornerstone acquisitions. As a result, we grew revenues in our first full year to over $1.4M in repeat physician customer sales. We are continuing to assess future strategic acquisitions of a similar nature that 1) add additional products and technologies complementary to our existing portfolio, 2) grow our physician client distribution base, and 3) generate higher revenues” stated QHSLab Chief Executive Officer Troy Grogan.

“As previously stated in our corporate materials, our market opportunity is comprised of over 250,000 independent U.S. primary care physicians, we’re currently generating $10,000 per physician practice per year and expect this metric to grow throughout 2022. It is estimated that over 70 percent of these physicians’ patients could benefit from the Company’s current portfolio of point-of-care and digital health products. From an industry perspective, the COVID-19 pandemic has heightened the need for and acceptance of digital healthcare, a trend our business model is strongly aligned with,” continued Grogan.

The following are some of the items discussed in the investor presentation update, which can be accessed by going to the Company’s website at https://www.usaqcorp.com/presentations :

  • Key company milestones highlighting significant financial and strategic progress over the past fiscal year
  • Detailed discussion of the proprietary AllergiEnd ® and Allergi QT  product line, including FDA-cleared diagnostic equipment and products allowing primary care providers to diagnose and treat many common chronic allergies in their offices
  • Highlights of QHSLab cloud-based software and IT system, a clinical decision support system currently addressing allergies and asthma, mental health, obstructive sleep apnea, and medical nutrition therapy
  • Profiles of QHSLab’s management and medical advisory team, which has a synergistic mix of industry experience, including comprehensive medical device, software and business development backgrounds
  • Continuing plan of strategic acquisitions, adding to our valuable product portfolio, and leveraging our growing client base of independent physician practices

 Forward-Looking Statements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Forward-Looking Statements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN  or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN  or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. Writer charges $1500  . All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly